UK markets close in 1 hour 1 minute

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.4000-0.1000 (-4.00%)
As of 10:11AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.97M
Enterprise value -6.17M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.54
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.36

Trading information

Stock price history

Beta (5Y monthly) 1.38
52-week change 3-62.09%
S&P500 52-week change 323.57%
52-week high 311.7700
52-week low 32.3600
50-day moving average 33.6685
200-day moving average 35.6260

Share statistics

Avg vol (3-month) 326.25k
Avg vol (10-day) 315.05k
Shares outstanding 51.17M
Implied shares outstanding 61.17M
Float 81.14M
% held by insiders 125.72%
% held by institutions 13.26%
Shares short (15 Apr 2024) 414.84k
Short ratio (15 Apr 2024) 40.88
Short % of float (15 Apr 2024) 41.71%
Short % of shares outstanding (15 Apr 2024) 41.27%
Shares short (prior month 15 Mar 2024) 423.86k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 301 Mar 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-55.20%
Return on equity (ttm)-164.09%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-15.19M
Diluted EPS (ttm)-12.9700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.14M
Total cash per share (mrq)7.8
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)1.25
Book value per share (mrq)1.65

Cash flow statement

Operating cash flow (ttm)-9.85M
Levered free cash flow (ttm)-2.75M